Myriad Genetics Inc (MYGN) reports robust revenue growth and strategic initiatives despite facing policy changes impacting ...

Myriad Genetics delivers strong third-quarter results, driven by growth within Pharmacogenomics and Prenatal. The company ...

Reports Q3 revenue $213M, consensus $210.73M. “During the third quarter of 2024, we grew revenue by 11%, compared to the third quarter of ...

In a report released today, Sung Ji Nam from Scotiabank reiterated a Buy rating on Veracyte (VCYT – Research Report), with a price target ...

Dominika's one-day-old daughter Emilia is part of the screening programme The entire genetic code of up to 100,000 newborn babies in England will be analysed by the NHS, with the aim of speeding ...

Using genetic engineering to modify crops can help ... Passaging doesn’t always work, however (5)—and when it does, it’s ...